|Home | About | Journals | Submit | Contact Us | Français|
Conceived and designed the experiments: RHX LJS. Performed the experiments: RHX SR XM FR. Analyzed the data: RHX LJS. Contributed reagents/materials/analysis tools: LJS. Wrote the paper: RHX LJS.
The extent to which direct- and cross-presentation (DP and CP) contribute to the priming of CD8+ T cell (TCD8+) responses to viruses is unclear mainly because of the difficulty in separating the two processes. Hence, while CP in the absence of DP has been clearly demonstrated, induction of an anti-viral TCD8+ response that excludes CP has never been purposely shown. Using vaccinia virus (VACV), which has been used as the vaccine to rid the world of smallpox and is proposed as a vector for many other vaccines, we show that DP is the main mechanism for the priming of an anti-viral TCD8+ response. These findings provide important insights to our understanding of how one of the most effective anti-viral vaccines induces immunity and should contribute to the development of novel vaccines.
Professional antigen presenting cells fragment viral proteins and display some of the resulting peptides bound to MHC molecules at the cell surface. When virus-specific CD8+ T cells recognize these viral peptides they become activated, proliferate, and kill virus-infected cells to help rid the body of the virus. Two pathways have been described for the origin of the peptides presented by professional antigen presenting cells. In cross-presentation, the antigen presenting cells acquire the proteins from other cells which, in the case of a viral infection, must be infected. In direct presentation, the antigen presenting cells synthesize the proteins themselves and, therefore, during responses to viruses must be infected. However, the participation of direct presentation in anti-viral responses has never been deliberately demonstrated experimentally. In this paper we demonstrate that direct presentation occurs and is the main pathway to induce CD8+ T cells during infection with vaccinia virus. These findings provide important insights to our understanding of how one of the most effective anti-viral vaccines induces immunity and should contribute to the development of novel vaccines.
Activated CD8+ T lymphocytes (TCD8+) kill virus infected cells that display virus-derived peptides presented on cell surface MHC I molecules. Hence, TCD8+ play an essential role in the clearance of many primary viral infections. Moreover, the memory TCD8+ that remain after a primary infection or vaccination can also participate in resistance to disease following a secondary infection ,,,. While most cells of the body express MHC I and can therefore be targets of TCD8+ killing, their initial activation and expansion (priming) during many viral infections requires antigen presentation by bone marrow-derived (BMD) professional antigen presenting cells (APC) ,,. The two major routes of MHC I antigen presentation are direct- and cross-presentation (DP and CP). In DP the Ag presenting cell synthesizes the Ag. Thus, DP presentation requires the infection of the Ag presenting cell. In CP, uninfected cells acquire the Ags from other infected cells. While most cells can engage in DP, CP is a function of phagocytic BMD APC such as DC and Μ ,. Several years ago we showed that when a virus cannot infect BMD APC, CP can still prime anti-viral TCD8+ . Since then, the specific role of CP and DP in priming anti-viral TCD8+ has been a topic of discussion with some arguing that CP is in general important or essential, whereas others propose that it is physiologically irrelevant ,,,,,. The main reason for this ongoing discussion is a dearth of direct data supporting DP or CP as the main mechanism of TCD8+ priming in viral infections . This most likely resulted from the difficulty in establishing appropriate experimental models that can exclude CP during an anti-viral response while maintaining similar levels of peptide-MHC complexes at the cell surface. For example, previous work by us and others has shown that (M)SIINFEKL expressed as a mini-gene during VACV infection is not a substrate for CP , and further earlier work by Restifo et al. and Wherry et al. , had shown that (M)SIINFEKL can prime TCD8+. Placing both pieces together, it could be argued that DP by VACV-infected cells has already been shown. However, because it does not require processing, VACV-(M)SIINFEKL infected cells express supra-physiologic Kb-SIINFEKL complexes at the surface of infected cells (~85,000 vs. 3,000 complexes per cell for VACV-full-length OVA ), has an extremely short half-life , and its ability to stimulate TCD8+ responses does not correlate with the very high levels MHC I-peptide complexes at the cell surface . Furthermore, whether this construct requires BMD APC has not been investigated. Similarly, Norbury et al. has shown that SIINFEKL embedded in a rapidly degraded construct (Ub-R-NP-SIINFEKL-EGFP) is not cross-presented but induces a TCD8+ response . However, while this construct requires processing, it is degraded very fast (10 minutes), resulting in faster Kb-SIINFEKL formation and at least three times more Kb-SIINFEKL complexes at the surface of infected cells as compared with a slowly degraded counterpart NP-SIINFEKL-EGFP . Understanding how TCD8+ are primed, in particular for those viruses that are useful as vaccines, is of major importance as it may directly impinge on vaccine efficacy. Here, we explore the role of DP and CP in the priming of TCD8+ to vaccinia virus (VACV) which was used as the vaccine that eliminated smallpox and is proposed as a vaccine vector for a number of infectious diseases and cancer ,.
Previous work by others showing clustering of TCR transgenic TCD8+ (TCD8+) with VACV infected APC suggested that DP can prime anti-VACV TCD8+ responses ,. However, this work did not formally prove that this clustering resulted in effective priming or TCD8+ expansion. To directly look into this issue, we made VACV-Kb+46-SIINFEKL-16, a double recombinant VACV co-expressing the MHC I molecule H-2 Kb and 46-SIINFEKL-16, a truncated form of chicken ovalbumin (OVA, 386 amino acids) comprising the Kb-restricted immunodominant determinant SIINFEKL preceded by 46 and followed by 16 amino acids from the natural OVA sequence. Of interest, this construct is a substrate for DP but not CP . As shown in Figure 1A, Kb-negative A9 cells infected with VACV-Kb+46-SIINFEKL-16 induced B3Z T cells, a T cell hybridoma that produces β-galactosidase (β-gal) upon recognition of Kb-SIINFEKL and can be used to compare amounts of Kb-SIINFEKL at the surface of cells ,. On the other hand, control A9 cells infected with VACV wild type (VACV-WT) or the single recombinants VACV-Kb and VACV-46-SIINFEKL-16, did not induce β-gal in B3Z cells. Additional controls showed that B3Z cells were induced when infecting Kb+ MC57G fibrosarcoma cells with VACV-Kb+46-SIINFEKL-16 or VACV-46-SIINFEKL-16 but not with VACV WT or VACV-Kb (not shown). Thus, virus encoded Kb can directly present virus encoded SIINFEKL in tissue culture. To determine whether virus-encoded Kb results in DP in vivo, B6.C-H2bm1/ByJ mice [bm1 mice; a C57BL/6 (B6) congenic strain carrying a mutant Kb allele (Kbm1)] were adoptively transferred with CFSE labeled splenocytes from OT-I TCR transgenic mice  and infected with various viruses. As shown in Figure 1B and C, the OT-I TCD8+ proliferated extensively and significantly increased in proportion relative to the endogenous TCD8+ population when the mice were infected with VACV-Kb+46-SIINFEKL-16 but not when infected with VACV-Kb or VACV-46-SIINFEKL-16. Some loss of CFSE fluorescence in a sizeable number of the OT-I cells in mice infected with VACV-46-SIINFEKL-16 (Figure 1B, center panel) was not reproducible (see the wide SD), and was most likely background because the proportion of OT-I cells did not increase significantly in these mice (Figure 1C). Similar results were obtained in the D-LN of mice inoculated IP and in the spleen and D-LN of mice inoculated SC (Figure S1A). In control experiments, VACV-46-SIINFEK-16 strongly stimulated OT-I cells in B6 mice (Figure 1B, right panel). Of note, the OT-I cells in B6 mice infected with VACV-46-SIINFEKL-16 expanded much more than in bm1 mice infected with VACV-Kb+46-SIINFEKL-16 as indicated by their significantly higher proportional increase (to 42.6±6.3% of total TCD8+, not shown) most likely indicating that Kb expressed by the virus cannot faithfully reproduce endogenous Kb expression. Regardless, because OT-I TCD8+ cells recognize SIINFEKL in the context of Kb but not of Kbm1 ,,, the results with bm1 mice strongly suggest that infected cells can directly present antigen to OT-I cells in vivo.
While OT-I cells have been used extensively to detect antigen presentation in vivo, there is the caveat that, because of their high TCR affinity, their priming requirements likely differ from those of a polyclonal naïve repertoire. In fact, their value as a tool in priming and T cell kinetics experiments has been questioned . Thus, to extend our findings to a polyclonal naïve repertoire we determined whether infection with a Kb-expressing virus can induced an endogenous TCD8+ response in bm1 mice. For this purpose, we infected bm1 mice with 106 PFU VACV-46-SIINFEKL-16 or VACV-Kb+46-SIINFEKL-16 and, seven days PI, we determined the endogenous TCD8+ responses to SIINFEKL and also to the dominant Kb-restricted genuine VACV determinant TSYKFESV  using appropriate Kb tetramers. We found that VACV-Kb+46-SIINFEKL-16 but not VACV-46-SIINFEKL-16 was able to stimulate significant anti-Kb-SIINFEKL and anti-Kb-TSYKFESV responses in the peritoneal cavity of bm1 mice (Figure 1D and E) demonstrating that VACV infected cells can use DP to expand polyclonal (non-transgenic) TCD8+ to the recombinant determinant SIINFEKL and also to TSYKFESV in bm1 congenic mice. Similar results where obtained for the spleens, peritoneal washes and lymph nodes of mice infected with 105 PFU of the viruses either IP or SC (Figure S1B, showing examples of two individual mice to demonstrate reproducibility). The response was Kb-peptide and not Kb-allo -specific because Kb-SIINFEKL tetramers stained a significant proportion of TCD8+ in bm1 mice infected with VACV-Kb+ 46-SIINFEKL-16 but not with VAC-Kb (Figure S1C and D). The data also indicate that the repertoire of bm1 mice includes at least some TCRs capable of recognizing TSYKFESV and SIINFEKL in the context of Kb. However, the response in bm1 mice, in particular against TSYKFESV, was much smaller than in B6 mice (see, for example, Figure 3D and E). This may be due to different expression of virus-encoded vs. endogenous Kb (as with the OT-I cells) and/or defective positive selection of Kb-restricted T cells in the bm1 thymus as previously reported by Nikolic-Zugic et al. . The fact that we detected Kb-SIINFEKL specific cells in bm1 mice while Nikolic-Zugic did not may be because we used a more potent antigenic stimulus (OVA encoded by VACV vs. OVA-loaded cells) and/or that they detected the responses using the 51Cr release assays while we used tetramer staining.
The previous data strongly suggested that DP can prime anti-VACV TCD8+. However, the experimental system had the caveat of using a semi-allogeneic system and that it does not distinguish between direct priming by infected cells of bone marrow vs. non-bone marrow (parenchymal) origin. We have previously used bone marrow chimeras with deficient expression of MHC I at the cell surface of BMD cells (from TAP1 deficient mice) to show that only BMD APC can prime TCD8+ responses to VACV and other viruses . Thus, to directly address the role of DP by BMD APC in the priming of endogenous TCD8+ responses, we reconstituted lethally irradiated B6 mice with bone marrow from mice deficient in H-2 Kb and Db (MHC I KO). Four months after reconstitution, most cells in the spleen, bone marrow (Figure 2A), and peritoneal wash (not shown) of MHC I KO→B6 mice lacked Kb and Db expression with the exception of a small residual population of cells in the bone marrow (~2%) and spleen (~5%), most of which were not “professional” APC because they lacked MHC II expression. Thus, the vast majority of professional APCs in aged MHC I KO →B6 mice lack DP as well as CP abilities due to deficient MHC I expression. However, because these APC lack MHC I but otherwise their antigen presentation machinery is intact, they could regain at least some DP capabilities if infected with a Kb-expressing virus. In addition, the APC in MHC I KO → B6 mice should also be capable of presenting pre-formed Kb-peptide complexes obtained thorugh membrane exchange (ME) with parenchymal cells, a mechanism of antigen presentation that was discovered somewhat recently ,,,,. Four months after reconstitution, the MHC I KO→B6 and B6→B6 control mice were infected with recombinant VACV-β-gal or with VACV-Kb. Seven days later, the anti-TSYKFESV TCD8+ response was measured in different organs by restimulating lymphocytes for 4 h with APC pulsed with TSYKFESV in the presence of brefeldin A followed by surface (CD8) and intracellular IFN-γ staining (IIS) and FACS analysis. We found that VACV-β-gal infection of MHC I KO→B6 mice resulted in an anti-TSYKFESV response in the spleen that was very reduced as compared to B6→B6 controls (Figure 2B), confirming our previous work  demonstrating that BMD APC are essential for the anti-VACV TCD8+. Moreover, this experiment shows that priming by ME (which was unknown at the time of our previous work) from parenchymal cells to APC does not play a dominant role in the anti-VACV TCD8+ response. More important, we found that much of the anti-TSYKFESV response was significantly restored when the MHC I KO→B6 chimeras were infected with VACV-Kb. Furthermore, MHC I KO→B6 mice mounted a significantly stronger response to TSYKFESV in the peritoneal wash when infected with VACV-Kb as compared with VACV-β-gal (Figure 2B). This strongly supports the hypothesis that BMD cells, but not parenchymal cells, infected with VACV can use DP to prime an endogenous polyclonal TCD8+ response to the VACV immunodominant determinant TSYKFESV.
To determine differences in DP by BMD APC vs parenchymal cells, we infected BMD DC (as a model for APC) and MC57G cells (as a model for parenchymal cells) with VACV 46-SIINFEKL-16 and measured the relative amount of Kb-SIINFEKL complex at the cell surface using B3Z cells (which do not require BMD APC for stimulation). We found that the two cell types were quantitatively comparable in their ability to stimulate B3Z cells indicating that they expressed roughly similar amounts of Kb-peptide complexes at the cell surface (Figure 2C). However, while infected WT DC primed an anti-VACV response in vivo, MC57G cells did not (Figure 2D). This strongly suggests that the difference in the ability of BMD APC vs parenchymal cells to prime TCD8+ to an Ag that needs processing is qualitative rather than quantitative and further suggested that DP or ME by parenchymal cells do not play a major role in the anti-VACV TCD8+ response. Of note, the priming following inoculation of infected DC was due to their expression of MHC and not to an adjuvant effect because infected DC deficient in MHC I did not induce an anti-VACV response (not shown).
The data thus far demonstrated that anti-VACV TCD8+ responses can be induced by DP. However, the experiments did not address to what extent DP and CP contribute to priming during VACV infection. Using a transfection/infection model, we have recently shown that during VACV infection, 61-SIINFEKL-121 (a truncated form of OVA comprising SIINFEKL preceded by 61 and followed by 121 AA of the natural OVA sequence) and 46-SIINFEKL-16 are processed for DP with similar efficiency. However, even though both constructs have extended half-lives, only 61-SIINFEKL-121 is processed for CP . Hence, we tested whether the antigenic properties of 61-SIINFEKL-121 and 46-SIINFEKL-16 were maintained when expressed in recombinant viruses. As expected, MC57G cells infected with either virus induced B3Z cells by DP with identical efficiency (Figure 3A). On the other hand, consistent with our results with the transfection/infection system , infection of A9 cells with recombinant VACV 61-SIINFEKL-121 but not with VACV 46-SIINFEKL-16 resulted in CP in vitro (Figure 3B) and CP to OT-I cells in vivo (Figure 3C). Next, we infected mice with 106 PFU of VACV 61-SIINFEKL-121 or VACV 46-SIINFEKL-16 IP and, using specific MHC tetramers, we determined the potency of the anti-SIINFEKL TCD8+ response in the peritoneal cavity and in the spleen. The anti-TSYKFESV response served as an internal control and to normalize the anti-SIINFEKL response. We did not find any significant difference between the two viruses (Figure 3D and 3E). Similar results were obtained for mice infected SC and/or with higher or lower viral doses (108 PFU and 104 PFU) determined by either tetramer staining or IIS (not shown). Because 46-SIINFEKL-16 is not cross-presented, these results imply that CP is dispensable for the induction of a maximal TCD8+ response during VACV infection independent of the dose or route.
It has been shown that pre-treatment of mice with the TLR9 ligand CpG induces maturation of DC, blocks CP, and inhibits the TCD8+ response to herpes simplex virus (HSV) and influenza virus in vivo . In our hands, this treatment also inhibited CP because mice treated with CpG had significantly reduced TCD8+ responses to SIINFEKL and TSYKFESV when inoculated IP with L cells that had been infected with VACV 61-SIINFEKL-121 to induce Ag expression, and then treated with UV light and paraformaldehyde to eliminate any traces of live virus (Figure 4A). However, CpG treatment did not significantly reduce priming of anti-SIINFEKL or anti-TSYKFESV TCD8+ in mice that had been infected with 103–106 PFU VACV 61-SIINFEKL-121 (Figure 4B–D) or VACV 46-SIINFEKL-16 (not shown), even though the potency of priming decreased with reduced virus dose. These results further imply that CP is dispensable for the induction of efficient anti-VACV TCD8+ responses following infection with live VACV. In fact, the only significant change that we observed with CpG treatment was an increase in the anti-TSYKFESV response in mice inoculated with 106 PFU. The reason for this increase is unknown but we speculate it may be due to an adjuvant effect of CpG. Why this increase was not observed for other viral doses or for SIINFEKL remains to be explored.
We have previously shown the strict requirement for BMD APC in the priming of TCD8+ responses to VACV and other viruses and that CP can prime TCD8+ when DP by BMD APC is abrogated ,. However, the extent whereby the DP and CP pathways contribute to an anti-viral response when both mechanisms are possible remained elusive because of the difficulty in ablating CP. Hence, priming of an anti-viral response exclusively by DP has never been demonstrated intentionally. In this paper we developed novel methods to disrupt CP and used them to demonstrate efficient priming of anti-VACV TCD8+ by DP following IP and SC inoculation. Furthermore, we show that when DP is available, CP is dispensable for eliciting a maximal anti-VACV TCD8+ response.
It has previously been shown that some anti-viral TCD8+ responses require or are partially dependent on CP. For instance, Shen et al. showed a decreased TCD8+ response to influenza virus in the absence of Cathepsin S, which is required for the processing of exogenous Ag via the TAP independent pathway  while Wilson et al. showed that inhibiting CP by administration of the TLR9 ligand inhibited the TCD8+ response to HSV 1. In the case of VACV, we and others have shown that VACV encoded Ags can indeed be cross-presented ,,. Attempts have also been made to quantify the contribution of CP and DP to the overall anti-VACV response. For instance, Gasteiger et al. has shown that the TCD8+ response to the MVA strain of VACV requires CP . However, the different requirements for this strain for VACV could be due to the fact that MVA is highly deficient in viral replication. Also, Basta et al. and Shen et al. , compared the TCD8+ responses to recombinant VACV expressing US2 and/or US11 from human cytomegalovirus (HCMV) US11, or β-gal as a control. Because these viruses induced TCD8+ responses to different degree depending on the route of infection, it was concluded that CP and DP contribute differentially to the anti-VACV TCD8+ response. However, the conclusions assumed that US2 and US11 shut down DP in vivo, which has never been demonstrated. Moreover, the conclusions were based on the presumption that molecules that inhibit the MHC I pathway could not maintain functionality and block CP when transferred from the Ag donor cell to the APC. However, more recent work from the Cresswell laboratory  showed that exogenous ICP47 from HSV (another protein that blocks MHC I Ag presentation) can block CP making the supposition doubtful. In addition, while the direct interaction between infected APCs and TCR transgenic cells specific for a virus encoded Ag has been shown ,, a clear demonstration of direct priming of naïve polyclonal anti-viral TCD8+ by infected APC expressing MHC I-peptide at relatively normal levels was still lacking. Here we have used four novel models to demonstrate that in vivo priming of anti-viral TCD8+ by DP occurs and that CP is dispensable to efficiently prime anti VACV TCD8+ in vivo. First, we used a semi-allogeneic model where the restricting MHC I and the Ag were exclusively encoded by VACV. Using this model we showed that following SC or IP infection, DP can stimulate TCR transgenic OT-I T cells and can also prime endogenous polyclonal responses to a recombinant (SIINFEKL) and an authentic (TSYKFESV) VACV determinant. It should be pointed out, however, that the OT-I responses in bm1 mice were not as strong as in B6 mice probably because the expression of endogenous MHC I cannot be faithfully replicated by virus-driven expression and, in the case of the endogenous responses, the repertoire capable of recognizing peptides in the context of Kb may be reduced in bm1 mice. Second, using bone marrow chimeras that lack expression of MHC I on BMD APC and infecting with VACV-Kb or control virus or inoculating with infected cells of bone marrow or parenchymal origin, we also showed priming by DP against TSYKFESV following IP or SC infection or DC inoculation. Further, we ruled out the transfer of preformed peptide MHC I complexes ,,,, from endogenous or inoculated parenchymal cells as a major mechanism for priming during VACV infection. In addition, these data also confirmed our earlier work that the priming of anti-VACV TCD8+ requires Ag presentation by BMDC . Third, by comparing TCD8+ responses to 46-SIINFEKL-16, a form of OVA that is not cross-presented and 61-SIINFEKL-121, a form of OVA that is cross-presented , we showed that CP is not essential for full-fledged TCD8+ responses to VACV independent of the route or dose of infection. Fourth, we showed that in vivo blockade of CP using the TLR9 ligand CpG does not inhibit the anti-VACV TCD8+ response as it did for HSV . Together, our experiments demonstrate that DP is the main mechanism for the priming of anti-VACV TCD8+.
Current models of Ag presentation mostly based on inert Ag suggest that APC acquire Ag in tissues, then mature, and finally migrate to the draining lymph node (D-LN) to prime T cells. While it is straightforward to imagine an uninfected APC loaded with Ag migrating to the D-LN, it is also possible to imagine that an APC infected with a cytopathic virus such as VACV would be migration-impaired. Thus, a remaining important question is to determine whether infected APC are still able to migrate to the D-LN following SC inoculation. Alternatively, free viral particles could reach the D-LN through afferent lymphatic capillaries as was shown with large inoculums of vesicular stomatitis virus  infecting D-LN resident APC. The site of priming following IP infection is more obscure and while it is possible that it occurs in the (para-thymic) D-LN, it is tempting to speculate that the peritoneal cavity, which has large nuber of BMD Μ, could act as a secondary lymphoid organ.
In summary our work demonstrates that DP is the main mechanism responsible for the priming of anti-VACV TCD8+ responses. These results are important for our general understanding of anti-viral TCD8+ immunity and for the use of VACV as a vaccine vector.
All experiments involving mice were performed according to Fox Chase Cancer Center guidelines for the care and use of laboratory animals and all animal studies were approved by the Fox Chase Cancer Center Institutional Animal Care and Use Committee.
All cells were grown at 37°C in an atmosphere of 5% CO2 in RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine, penicillin-streptomycin, 0.01 M HEPES buffer and 5×10−5 M 2-ME (Sigma-Aldrich, St. Louis, MO). As L cells (H-2K) we used its derivative A9 (ATCC no. CCL-1.4). L cells stably expressing Kb (L-Kb) , were a gift from Drs. Yewdell and Bennink. MC57G cells (ATCC no. CRL-2295) are a C57BL/6 fibrosarcoma (H-2b). B3Z is a CD8 T cell hybridoma that produces β-gal upon recognition of SIINFEKL in the context of the H-2Kb molecule  without the need of costimulation. Hela S3 (CCL –2.2) and BS-C-1 (CCL-26) were used to propagate virus and determine VACV titer. In vitro differentiation of DC and Μ from bone marrow was as previously described .
VACV stocks were prepared as described  VACV-46-SIINFEKL-16 and VACV-61-SIINFEKL-121 were previously described . The VACV-Kb in Figure 2 was a gift from Drs. Jonathan Yewdell and Jack Bennink (NIH, Bethesda, Maryland) and co-expresses β-gal and Kb disrupting the TK gene. VACV-β-gal was generated by homologous recombination into the TK gene using the plasmid pSC65 as described . The VACV-kb in Figure 1, VACV-Kb+46-SIINFEKL-16 and VACV 61-SIINFEKL-121 were generated by homologous recombination using appropriate constructs inserted in the plasmid pRB21 and selection of large plaques as described . The correct sequence of the recombinant proteins was verified by sequencing PCR fragments amplified from viral DNA.
C57BL/6 (B6) were from Fox Chase Cancer Center stock. B6.C-H2bm1/ByJ (bm1, stock #001060) B6.PL-Thy1a/CyJ (B6-Thy1.1, stock # 000406), B6.129S7-Rag1tm1Mom/J and (Rag1 KO stock # 002216) were bred at FCCC from mice purchased from Jackson Laboratories (Bar Harbor, Maine). H-2Kbtm1, H-2Dbtm1 (MHC I KO, stock # 004215-MM) were purchased from the Emerging Models Program at Taconic Farms (Germantown, NY) and bred at FCCC. OT-I mice , originally a gift from Dr. Stephen Jameson (University of Minnesota, MN), were bred with Rag1 KO and B6-Thy1.1 to homozygosity at FCCC. Bone marrow chimeras were prepared as previously described , using 5–7 weeks old mice as donors and recipients. Except for bone marrow chimeras, all experiments used mice between 6–12 weeks of age. Mice were infected or injected with infected cells as indicated. Bone marrow chimeras were prepared as previously described ,. For CpG treatment, mice were injected intravenously in the tail vein with 20 nM synthetic phosphorothioated CpG1668 (Integrated DNA Technologies Inc, Coralville, IA) .
In vitro DP and in vitro and in vivo CP assays were performed as previously described , except that for Ag expression we used recombinant viruses rather than plasmid transfection and infection with WT virus. Thus, for in vivo and in vitro CP, the virus was inactivated by UV irradiating the Ag donor cells as described  and fixing with 2% paraformaldehyde overnight followed by extensive washing. To determine DP by inoculated cells, DC or MC57G cells were infected with VACV, 10 PFU/cell for 1 h, thoroughly washed, and 106 were inoculated into mice as indicated.
Determination of proliferation and expansion of CFSE labeled OT-I cells was as before . IIS was performed as previously described ,, except that in some cases, instead of infected cells, the virus-specific TCD8+ were restimulated with cells pulsed in complete media with 1 µM synthetic peptides (Genscript corp) for 1 h in CRPMI and thoroughly washed. Kb-tetramers were produced and used exactly as described  except that the SIINFEKL or TSYKFESV peptide were used for the refolding reaction.
One- or two-tailed T test analyses were used according to the hypothesis being tested. Tests were performed using the Graph Pad Prism software.
Direct presentation can prime anti-VACV TCD8+. A) bm1 mice were adoptively transferred with 106 CFSE labeled OT-I cells and infected IP with 106 PFU of the indicated viruses. OT-I proliferation was determined by FACS on day 4 PI. Data correspond to a pool of three mice and is representative of three experiments. B) bm1 mice were infected with 105 PFU of the indicated viruses IP or SC. Seven days later the SIINFEKL and TSYKFESV-specific TCD8+ were determined in the indicated organs by staining with the indicated Kb tetramers. Data correspond to two individual mice from groups of two and is representative of three similar experiments. Data is gated on CD8+ cells. C) bm1 were infected IP with 106 PFU of the indicated viruses and surface staining with CD8 and the indicates tetramers was performed in splenocytes on day 7 PI. Plots are from a representative mouse and gated on CD8+ cells. The graph on the right is the summary for three mice in each group. Gray columns, stained with Kb-TSYKFESV tetramers; white columns, stained with Kb-SIINFEKL tetramers. Columns represent the average ±SD of three mice. P values from one-tailed T tests. D) Mice were infected SC with 106 of the indicated viruses and seven days later the SIINFEKL and TSYKFESV-specific TCD8+ were determined in the indicated organs by staining with Kb-SIINFEKL and Kb-TSYKFESV tetramers. Graphs show the ratio of Kb-TSYKFESV+/Kb-SIINFEKL+ staining for three mice/group. No significant differences between viruses were found by two-tailed T test analysis.
(1.13 MB PDF)
We thank Fox Chase Cancer Center Laboratory Animal, Flow Cytometry, Sequencing, Imaging and Biostatistics Facilities. We also thank Ms. Holly Gillin for assistance in the preparation of the manuscript, Dr. Samuel Litwin for help with the statistical analysis of the data, and Drs. Laurence Eisenlohr (Thomas Jefferson University) and Glenn Rall (FCCC) for critical reading of the manuscript.
The authors have declared that no competing interests exist.
This work was supported by NIH R01AI048849 to LJS and CA006927 to FCCC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.